The medtech industry is entering a pivotal new phase. It’s being defined by meaningful innovation, disciplined capital, and a growing focus on technologies that improve care delivery and early disease detection.

PitchBook’s Q3 2025 Medtech VC & PE Trends report shows an ecosystem operating at two speeds: later-stage, high-quality platforms continue to attract significant investment, while early-stage startups without clear AI or commercialization pathways face mounting pressure. Venture funding reached $3.0B in Q3, which is down from Q2’s $4.6B, but is still on pace to make 2025 the strongest year since 2023. This underscores the importance of backing companies that pair breakthrough science with credible paths to market adoption.

Public markets have reemerged as medtech’s most reliable exit engine, with IPOs accounting for over 90% of exit value year-to-date. Listings from Caris Life Sciences, Heartflow, and Kestra Medical Technologies demonstrate renewed confidence in the category, even as traditional M&A remains selective. Boston Scientific continues to be a notable exception with an active acquisition strategy, but overall valuation gaps are pushing founders toward hybrid exit models. This is evident in the $2.3B HistoSonics transaction backed by both public and private investors. These shifts reinforce what we see at Seed: when commercialization traction is strong, exit pathways widen.

Surgical devices and tools remain the backbone of medtech innovation, representing nearly 40% of all venture deal value over the past year. Robotics, cardiovascular interventions, neurostimulation, and brain–computer interface platforms (like Neuralink’s $650M raise) are shaping the next era of minimally invasive and advanced therapeutic care. Meanwhile, diagnostics and life sciences are experiencing renewed momentum, supported by a wave of IPOs and rising strategic interest. This aligns directly with Seed Healthcare’s mission: empowering early detection, precision diagnostics, and preventative platforms that meaningfully reduce disease burden at scale.

Perhaps the strongest forward signal is AI’s continued expansion into practical, device-level applications. From AI-powered imaging and surgical navigation to smart implants and genomic interpretation, AI is maturing from a software layer into core clinical infrastructure. Partnerships across major players, such as Google Cloud, NVIDIA, Medtronic, GE HealthCare, and Dexcom, highlight how the industry is shifting from experimentation to implementation.

Takeaway

For founders, it’s a call to build with clinical utility in mind. For investors, it’s a reminder that the companies best positioned for long-term value creation are those integrating AI with proven commercialization models and measurable patient impact.